EHA Library - The official digital education library of European Hematology Association (EHA)

INFLUENCE OF LENALIDOMIDE USED IN INDUCTION PERIOD AND INTENSITY OF MOBILIZATION REGIMEN ON THE NUMBER OF CD34+ CELLS HARVESTED IN PATIENTS WITH MULTIPLE MYELOMA
Author(s): ,
Ivan Kostroma
Affiliations:
Bone marrow transplantation department,Russian Institute of Hematology and Transfusiology,St.Petersburg,Russian Federation
,
Ananstasiya Zhernaykova
Affiliations:
Bone marrow transplantation department,Russian Institute of Hematology and Transfusiology,St.Petersburg,Russian Federation
,
Zhana Chubukina
Affiliations:
Immunologic laboratory ,Russian Institute of Hematology and Transfusiology,St.Petersburg,Russian Federation
,
Irina Zapreeva
Affiliations:
Bone marrow transplantation department,Russian Institute of Hematology and Transfusiology,St.Petersburg,Russian Federation
,
Natalya Semenova
Affiliations:
Research laboratory of leukemia ,Russian Institute of Hematology and Transfusiology,St.Petersburg,Russian Federation
,
Stanislav Bessmeltsev
Affiliations:
Hematological clinic,Russian Institute of Hematology and Transfusiology,St.Petersburg,Russian Federation
,
Alexander Chechetkin
Affiliations:
Hematological clinic,Russian Institute of Hematology and Transfusiology,St.Petersburg,Russian Federation
Sergey Gritsaev
Affiliations:
Bone marrow transplantation department,Russian Institute of Hematology and Transfusiology,St.Petersburg,Russian Federation
(Abstract release date: 05/17/18) EHA Library. Kostroma I. 06/14/18; 216058; PB2477
Ivan Kostroma
Ivan Kostroma
Contributions
Abstract

Abstract: PB2477

Type: Publication Only

Background
Recovery of hematopoiesis after autologous stem cell transplantation (AutoSCT) depends on the count of the harvested CD34+ cells. It is supposed that count and proliferative capacity of mobilized stem cells are influenced by the kind of previous therapy and variety of chemotherapy agents used in the mobilization regimen.

Aims
The aim of the study was to determine prognostic significance of premobilization lenalidomide apply and the sort of mobilizatrion regimen (cyclophosphomide or vinorelbine) on the number of CD34+ cells in the autotransplant of multiple myeloma (MM) patients.

Methods
We examined the data of autotransplant harvesting in 68 patients retrospectively. Mobilization regimens with vinorelbine 35 mg/m/2 (23 patients) and cyclophosphamide 3.0 g/m/2 (45 patients) were used. 21 patients (30.9%) were treated with lenalidomide previously. In the group of patients treated with lenalidomide 14 patients were mobilized with vinorelbine and 7 patients with cyclophospamide. 

Results
Mobilization failure with the number of CD34+ cells less than 2x10/6/kg was fixed in 5 patients (7.4%). There was no any difference in CD34+ cells number in groups of patients according to the age and MM variant. We found the trend with decreasing of CD34+ cells number in patients treated with lenalidomide: 4.1x10/6/kg (0.27-23.29) vs 6.76x10/6/kg (0.58-29.13) in patients who were not treated with lenalidomide; p=0.066. There was significant difference in the count of CD34+ cells harvested after cyclophospomide plus G-CSF and vinorelbine plus G-CSF: 6.8x10/6/kg (0.53-29.13) vs 3.96x10/6/kg (0.27-9.66) accordingly; p=0.022.

Conclusion
We conclude that vinorelbine plus G-CSF is a mobilization regimen of choice for older patients who were not treated with lenalidomide aggressively in the premobilization period and for whom the single AutoSCT is planned.

Session topic: 23. Stem cell transplantation - Clinical

Abstract: PB2477

Type: Publication Only

Background
Recovery of hematopoiesis after autologous stem cell transplantation (AutoSCT) depends on the count of the harvested CD34+ cells. It is supposed that count and proliferative capacity of mobilized stem cells are influenced by the kind of previous therapy and variety of chemotherapy agents used in the mobilization regimen.

Aims
The aim of the study was to determine prognostic significance of premobilization lenalidomide apply and the sort of mobilizatrion regimen (cyclophosphomide or vinorelbine) on the number of CD34+ cells in the autotransplant of multiple myeloma (MM) patients.

Methods
We examined the data of autotransplant harvesting in 68 patients retrospectively. Mobilization regimens with vinorelbine 35 mg/m/2 (23 patients) and cyclophosphamide 3.0 g/m/2 (45 patients) were used. 21 patients (30.9%) were treated with lenalidomide previously. In the group of patients treated with lenalidomide 14 patients were mobilized with vinorelbine and 7 patients with cyclophospamide. 

Results
Mobilization failure with the number of CD34+ cells less than 2x10/6/kg was fixed in 5 patients (7.4%). There was no any difference in CD34+ cells number in groups of patients according to the age and MM variant. We found the trend with decreasing of CD34+ cells number in patients treated with lenalidomide: 4.1x10/6/kg (0.27-23.29) vs 6.76x10/6/kg (0.58-29.13) in patients who were not treated with lenalidomide; p=0.066. There was significant difference in the count of CD34+ cells harvested after cyclophospomide plus G-CSF and vinorelbine plus G-CSF: 6.8x10/6/kg (0.53-29.13) vs 3.96x10/6/kg (0.27-9.66) accordingly; p=0.022.

Conclusion
We conclude that vinorelbine plus G-CSF is a mobilization regimen of choice for older patients who were not treated with lenalidomide aggressively in the premobilization period and for whom the single AutoSCT is planned.

Session topic: 23. Stem cell transplantation - Clinical

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies